Caribbean men are to benefit from research into prostate cancer first carried out in Bermuda.

The Caribbean Prostate Cancer Genetic Study is now targeting 1,000 men with free PSA tests in an effort to provide early diagnoses and potentially save lives.

The Bermuda study launched two years ago when a total of 160 men were tested on the island, with a further 157 tested in St Lucia from last year until now.

It was discovered that six men from the 317 who took part had the disease.

Now the programme has moved to Grenada in conjunction with St George’s University.

CariGenetics is the firm behind the project and founder and chief executive Carika Weldon said: “This Grenada cohort follows the Bermuda cohort, which launched in 2024 and was completed in 2025, and the St Lucia cohort, which launched in 2025 and completed a few months ago.

“We have seen some very promising results on how we can actually catch prostate cancer earlier.

“We are very excited to bring the same research to Grenada.”

A CariGenetics spokesman said, “Prostate cancer is one of the most common cancers among Caribbean men and, for too long, the tools to detect it have not been built with us in mind.

“The Caribbean Prostate Cancer Genetic Study is changing that with 1,000 men across multiple Caribbean populations and free PSA tests, early diagnoses, lives saved.

“We are proud to do this work alongside our partners at Oxford Nanopore Technologies, whose technology makes rapid, information-rich DNA analysis possible anywhere in the world, including here in the Caribbean.

“Early detection saves lives. If you are uninsured or underinsured, CariGenetics now offers PSA testing for $50 in Bermuda — because men deserve to know.”

He added: “Grenada now becomes our third country in this study, allowing us improve our understanding of prostate cancer risk in men of Caribbean ancestry, supporting earlier detection, better outcomes and healthier futures.”

A PSA, or prostate-specific antigen test, is a blood test to help detect prostate problems, including cancer.